Login
Home
Charts
Search
Watchlist
Products

Religare Enterprises Ltd

RELIGARE·NSE
249.17-1.60%Tue, 22 Sept '26 15:56

Religare Enterprises Ltd

RELIGARE
NSE
249.17
-1.60%
|Tue, 22 Sept '26 15:56
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
8,568Cr
Close
Close Price
248.55
Industry
Industry
Finance - Insurance
PE
Price To Earnings
166.81
PS
Price To Sales
0.96
Revenue
Revenue
8,954Cr
Rev Gr TTM
Revenue Growth TTM
19.01%
PAT Gr TTM
PAT Growth TTM
-89.00%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
1,5841,5111,8561,7101,9521,6682,0421,8612,0772,0562,4672,353
Growth YoY
Revenue Growth YoY%
36.129.632.933.123.210.410.08.96.423.320.826.4
Expenses
ExpensesCr
1,4831,4551,8331,6531,8761,7301,8051,8462,0102,1512,3252,402
Operating Profit
Operating ProfitCr
10156235776-612371567-95143-49
OPM
OPM%
6.43.71.23.33.9-3.711.60.83.2-4.65.8-2.1
Other Income
Other IncomeCr
127195192810121265
Interest Expense
Interest ExpenseCr
25241813135671091015
Depreciation
DepreciationCr
181817161514171312111218
PBT
PBTCr
59412363367-79222657-103127-77
Tax
TaxCr
197556-1-1671-212-2732-30
PAT
PATCr
40341812769-63151846-7796-47
Growth YoY
PAT Growth YoY%
122.8135.1-94.8-71.070.0-288.3-16.7-69.7-33.1-21.1-36.5-678.6
NPM
NPM%
2.52.29.81.63.5-3.87.40.42.2-3.73.9-2.0
EPS
EPS
0.80.63.80.61.6-1.33.00.31.2-1.42.5-0.8
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
1,5841,5111,8561,7101,9521,6682,0421,8612,0772,0562,4672,353
Growth YoY
Revenue Growth YoY%
36.129.632.933.123.210.410.08.96.423.320.826.4
Expenses
ExpensesCr
1,4831,4551,8331,6531,8761,7301,8051,8462,0102,1512,3252,402
Operating Profit
Operating ProfitCr
10156235776-612371567-95143-49
OPM
OPM%
6.43.71.23.33.9-3.711.60.83.2-4.65.8-2.1
Other Income
Other IncomeCr
127195192810121265
Interest Expense
Interest ExpenseCr
25241813135671091015
Depreciation
DepreciationCr
181817161514171312111218
PBT
PBTCr
59412363367-79222657-103127-77
Tax
TaxCr
197556-1-1671-212-2732-30
PAT
PATCr
40341812769-63151846-7796-47
Growth YoY
PAT Growth YoY%
122.8135.1-94.8-71.070.0-288.3-16.7-69.7-33.1-21.1-36.5-678.6
NPM
NPM%
2.52.29.81.63.5-3.87.40.42.2-3.73.9-2.0
EPS
EPS
0.80.63.80.61.6-1.33.00.31.2-1.42.5-0.8

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
4,4323,7722,5242,2872,3552,4923,2244,6766,2357,3788,4598,954
Growth
Revenue Growth%
8.0-14.9-33.1-9.43.05.829.345.133.318.314.719.0
Expenses
ExpensesCr
2,0601,6682,8453,0292,3472,2443,6104,2105,9177,0638,3248,888
Operating Profit
Operating ProfitCr
2,3722,104-320-7438248-38746731831513666
OPM
OPM%
53.555.8-12.7-32.50.310.0-12.010.05.14.31.60.7
Other Income
Other IncomeCr
7169211115423814918764273435
Interest Expense
Interest ExpenseCr
1,8721,8361,26885084972574062894373643
Depreciation
DepreciationCr
363130266159535672624752
PBT
PBTCr
282-136-1,407-1,504-1,030-497-1,0313,259448243875
Tax
TaxCr
222-13-227-38-20507901006114-13
PAT
PATCr
60-123-1,181-1,501-1,038-478-1,5393,1693471837318
Growth
PAT Growth%
-81.2-304.6-857.0-27.130.954.0-222.0305.9-89.0-47.4-60.0-89.0
NPM
NPM%
1.4-3.3-46.8-65.6-44.1-19.2-47.767.85.62.50.90.2
EPS
EPS
-2.9-9.8-58.6-63.3-39.5-19.6-51.396.17.13.82.61.5
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
4,4323,7722,5242,2872,3552,4923,2244,6766,2357,3788,4598,954
Growth
Revenue Growth%
8.0-14.9-33.1-9.43.05.829.345.133.318.314.719.0
Expenses
ExpensesCr
2,0601,6682,8453,0292,3472,2443,6104,2105,9177,0638,3248,888
Operating Profit
Operating ProfitCr
2,3722,104-320-7438248-38746731831513666
OPM
OPM%
53.555.8-12.7-32.50.310.0-12.010.05.14.31.60.7
Other Income
Other IncomeCr
7169211115423814918764273435
Interest Expense
Interest ExpenseCr
1,8721,8361,26885084972574062894373643
Depreciation
DepreciationCr
363130266159535672624752
PBT
PBTCr
282-136-1,407-1,504-1,030-497-1,0313,259448243875
Tax
TaxCr
222-13-227-38-20507901006114-13
PAT
PATCr
60-123-1,181-1,501-1,038-478-1,5393,1693471837318
Growth
PAT Growth%
-81.2-304.6-857.0-27.130.954.0-222.0305.9-89.0-47.4-60.0-89.0
NPM
NPM%
1.4-3.3-46.8-65.6-44.1-19.2-47.767.85.62.50.90.2
EPS
EPS
-2.9-9.8-58.6-63.3-39.5-19.6-51.396.17.13.82.61.5

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
178178178217258259319324330331333
Reserves
ReservesCr
3,6602,5471,658521-157-307-1,3011,7342,0102,1852,212
Current Liabilities
Current LiabilitiesCr
10,3048,0912,6252,6243,1324,0745,6794,7246,0587,63910,331
Non Current Liabilities
Non Current LiabilitiesCr
13,0779,6998,9835,9024,8044,3544,217692241106297
Total Liabilities
Total LiabilitiesCr
27,42921,03813,8629,5788,1308,7269,3648,0949,47411,18014,506
Current Assets
Current AssetsCr
9,4968,6302,9252,4642,2942,3974,0101,8591,9311,8432,674
Non Current Assets
Non Current AssetsCr
17,93412,40810,9387,1145,8366,3295,3536,2357,5429,33711,831
Total Assets
Total AssetsCr
27,42921,03813,8629,5788,1308,7269,3648,0949,47411,18014,506
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
178178178217258259319324330331333
Reserves
ReservesCr
3,6602,5471,658521-157-307-1,3011,7342,0102,1852,212
Current Liabilities
Current LiabilitiesCr
10,3048,0912,6252,6243,1324,0745,6794,7246,0587,63910,331
Non Current Liabilities
Non Current LiabilitiesCr
13,0779,6998,9835,9024,8044,3544,217692241106297
Total Liabilities
Total LiabilitiesCr
27,42921,03813,8629,5788,1308,7269,3648,0949,47411,18014,506
Current Assets
Current AssetsCr
9,4968,6302,9252,4642,2942,3974,0101,8591,9311,8432,674
Non Current Assets
Non Current AssetsCr
17,93412,40810,9387,1145,8366,3295,3536,2357,5429,33711,831
Total Assets
Total AssetsCr
27,42921,03813,8629,5788,1308,7269,3648,0949,47411,18014,506

Cash Flow

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
-2,1545,8715,8023,5542,4331,3731,5961,5061,5001,5231,820
Investing Cash Flow
Investing Cash FlowCr
5152,318-457-62-436-1,181-689-939-1,348-1,185-2,176
Financing Cash Flow
Financing Cash FlowCr
1,853-7,696-6,455-3,786-1,743-314559-2,079-156-285690
Net Cash Flow
Net Cash FlowCr
214492-1,110-294254-1221,466-1,512-453334
Free Cash Flow
Free Cash FlowCr
-2,2015,8565,7763,5282,4101,3551,5571,4661,4791,4991,809
CFO To PAT
CFO To PAT%
-3,572.8-4,758.9-491.5-236.8-234.4-287.4-103.747.5431.7833.62,487.5
CFO To EBITDA
CFO To EBITDA%
-90.8279.1-1,811.7-478.630,403.9552.9-412.6322.7471.4483.41,341.6
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
-2,1545,8715,8023,5542,4331,3731,5961,5061,5001,5231,820
Investing Cash Flow
Investing Cash FlowCr
5152,318-457-62-436-1,181-689-939-1,348-1,185-2,176
Financing Cash Flow
Financing Cash FlowCr
1,853-7,696-6,455-3,786-1,743-314559-2,079-156-285690
Net Cash Flow
Net Cash FlowCr
214492-1,110-294254-1221,466-1,512-453334
Free Cash Flow
Free Cash FlowCr
-2,2015,8565,7763,5282,4101,3551,5571,4661,4791,4991,809
CFO To PAT
CFO To PAT%
-3,572.8-4,758.9-491.5-236.8-234.4-287.4-103.747.5431.7833.62,487.5
CFO To EBITDA
CFO To EBITDA%
-90.8279.1-1,811.7-478.630,403.9552.9-412.6322.7471.4483.41,341.6

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
5,0883,8779656384902,2724,1494,6936,9037,7676,7268,568
Price To Earnings
Price To Earnings
1.529.662.378.3166.8
Price To Sales
Price To Sales
1.01.10.40.30.20.91.31.01.11.10.81.0
Price To Book
Price To Book
1.31.40.50.94.9-48.1-4.22.33.03.12.63.0
EV To EBITDA
EV To EBITDA
8.16.2-28.6-8.2548.125.9-17.09.919.421.840.0114.3
Profitability Ratios
Profitability Ratios
GPM
GPM%
100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
OPM
OPM%
53.555.8-12.7-32.50.310.0-12.010.05.14.31.60.7
NPM
NPM%
1.4-3.3-46.8-65.6-44.1-19.2-47.767.85.62.50.90.2
ROCE
ROCE%
10.912.3-1.2-8.8-3.34.7-7.6139.420.210.64.24.2
ROE
ROE%
1.6-4.5-64.3-203.5-1,027.51,014.8156.6154.014.87.32.92.9
ROA
ROA%
0.2-0.6-8.5-15.7-12.8-5.5-16.439.13.71.60.50.5
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
5,0883,8779656384902,2724,1494,6936,9037,7676,7268,568
Price To Earnings
Price To Earnings
1.529.662.378.3166.8
Price To Sales
Price To Sales
1.01.10.40.30.20.91.31.01.11.10.81.0
Price To Book
Price To Book
1.31.40.50.94.9-48.1-4.22.33.03.12.63.0
EV To EBITDA
EV To EBITDA
8.16.2-28.6-8.2548.125.9-17.09.919.421.840.0114.3
Profitability Ratios
Profitability Ratios
GPM
GPM%
100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
OPM
OPM%
53.555.8-12.7-32.50.310.0-12.010.05.14.31.60.7
NPM
NPM%
1.4-3.3-46.8-65.6-44.1-19.2-47.767.85.62.50.90.2
ROCE
ROCE%
10.912.3-1.2-8.8-3.34.7-7.6139.420.210.64.24.2
ROE
ROE%
1.6-4.5-64.3-203.5-1,027.51,014.8156.6154.014.87.32.92.9
ROA
ROA%
0.2-0.6-8.5-15.7-12.8-5.5-16.439.13.71.60.50.5
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Religare Enterprises is a holding company that builds and backs financial-services businesses, but it is now being deliberately dismantled into two separate listed entities - one a pure health insurer and the other a lending-and-broking platform - so that each can be valued on its own economics. The group was founded as Religare Enterprises, seeded its operating businesses over time, and spent years cleaning up legacy irregularities after the original promoters exited in 2018; the Burman Group became the designated promoter in February 2025 and held roughly 30% by the last quarter of FY26. The recurring approach is to run each vertical under an independent professional management team, charge subsidiaries a nominal fee for corporate services, and generate returns from dividends and capital gains - a structure that is now being unwound through a demerger that will give every REL shareholder one share in the spun-off lending-and-broking company for every REL share they hold. # Business segments Four engines at different stages - a health-insurance powerhouse that dominates the standalone market, a full-service broking and e-governance platform with over a million clients, an MSME lender rebuilt from a near-death regulatory freeze, and a small-ticket affordable-housing finance company - soon to be split into two listed groups. ## 1. Care Health Insurance: the group’s earnings engine and future standalone identity **India’s second-largest standalone health insurer, built on a retail-first book that grew at a 30% compound rate over four years and processes nearly nine in ten cashless claims in under an hour.** - **Retail health is the core** - retail policies make up 66% of the business, and that share improved by five percentage points year-on-year, because the company deliberately tilts toward individual and family plans rather than lumpy corporate group accounts. - **Digital claims keep customers sticky** - over 87% of cashless claims are settled in less than one hour, 96% of policies are issued digitally, and the mobile app has 12.5 million installations with 1.2 million monthly active users, which together produce a claims Net Promoter Score of 64. - **A multi-channel distribution net** - roughly 4.11 lakh agents (about 50,000 added in FY26 alone), 239 corporate agents and bancassurance partners, and 660 brokers feed the book, with the agency channel contributing 42% of total gross written premium. - **The hospital network is the infrastructure moat** - over 22,040 hospital tie-ups and more than 1,455 network locations mean the insurer can offer cashless treatment almost anywhere, which is what makes a health policy sellable in a country with no dominant hospital chain. - **An investment book that now earns better** - the roughly INR 10,944 crore portfolio yields 7.3%, and a credit-rating upgrade to the AA family during FY26 let the company raise sub-debt of INR 100 crores, lowering its cost of capital. ## 2. Religare Finvest: the rebuilt MSME lender, soon to be the listed face of the non-insurance group **A middle-layer NBFC that once ran a loan book of over INR 16,000 crores, was frozen under a regulatory corrective action plan for seven years, repaid more than INR 9,200 crores to banks, and is now debt-free with a clean slate and surplus cash.** - **The regulatory freeze is lifted** - the RBI withdrew its Corrective Action Plan in July 2025, and the Delhi High Court quashed the fraud classification by 14 lenders on the same day, so the company can now lend freely for the first time since January 2018. - **A fortress balance sheet by design** - net owned funds stand at INR 821 crores, tangible net worth is roughly INR 900 crores, and the capital-to-risk-weighted-assets ratio is 261%, which is multiples of the regulatory minimum and means the company can grow its book without raising fresh equity immediately. - **The legacy book is tiny and clean** - the core SME book is only about INR 60-odd crores, collection efficiency runs at around 98%, and net non-performing assets are roughly 0.8%, so there is no hangover of bad loans to work through. - **Lending to the fragmented SME economy** - the portfolio spans over 80 industries, and products range from working-capital loans to secured business-expansion loans and trade finance, with SME finance already over 22% of the lending business as of March 2025. ## 3. Religare Broking: the client franchise and e-governance utility **A full-service stockbroker with over a million registered clients and a parallel e-governance business that processes PAN cards for more than 5.2 crore customers - two cash-generating distribution networks under one roof.** - **A full-service broking platform with a discount option** - clients can trade cash equities, equity derivatives, commodities, and currencies through branches, web, a mobile app called Dynami, or call-and-trade, and the firm is a member of NSE, BSE, MSEI, NCDEX, and MCX. - **Assets under custody signal client trust** - INR 38,745 crores in custody assets across roughly 250,000 active clients and about 140,000 unique traded clients annually means the franchise is more than just churn; it holds sticky balances. - **The e-governance business is a separate distribution machine** - operating through roughly 61,000 business partners, it commands a 19% market share in PAN services and also handles TAN, e-TDS returns, bill payments, recharges, and ticketing, growing 13% year-on-year in FY26. - **Bancassurance partnerships widen the funnel** - tie-ups with seven banks including Union Bank of India, Karur Vysya Bank, and South Indian Bank give the broking arm access to bank customers who might not walk into a standalone brokerage branch. ## 4. Religare Housing Finance: the small-ticket affordable-housing play **An affordable housing finance company that makes home loans averaging INR 10-11 lakhs to self-employed and salaried borrowers in Tier-2 and Tier-3 cities, with a loan-to-value ratio of about 50% and all loans backed by residential property.** - **Lending to the under-penetrated mortgage market** - India’s mortgage penetration is only about 11% of GDP, compared with 28% in China and 71% in the USA, so the addressable pool of first-time homebuyers in small cities is large. - **Conservative underwriting by design** - the average loan-to-value ratio is roughly 50%, the capital adequacy ratio is about 130%, and no loan restructuring has been undertaken, which together explain how gross NPAs are contained at 3.5%. - **Co-lending partnerships stretch the balance sheet** - the company originates loans, 80% of which are funded by one HFC and two NBFC partners, while RHDFCL manages the loans and earns interest spread and fee income on the off-book assets under management. - **A branch-light model for small towns** - about 15 branches across 8 states serve roughly 3,100 customers, with a product mix of roughly two-thirds home loans and one-third loan against property, and a customer base that is 57% self-employed non-professionals. # Group structure and partners **The group is being split in two: REL will become a pure health-insurance holding company, while Religare Finvest will inherit the lending, broking, and e-governance businesses and list separately.** - REL is the listed Core Investment Company; the Burman Group is the promoter with roughly 30.3% as of the last quarter of FY26, held through four NBFC entities. - REL owns 63.20% of Care Health Insurance, 100% of Religare Broking, and 100% of Religare Finvest; Religare Finvest in turn owns 87.5% of Religare Housing Finance, with the remaining 12.5% held by the Maharishi Housing Development Trust. - The demerger scheme approved by the boards in February 2026 will transfer the lending, broking, investment, and ancillary businesses into Religare Finvest, cancel REL’s existing stake in RFL, and issue one RFL share for every REL share held, with RFL then listing on BSE and NSE - targeted for completion in the first quarter of FY28. - Religare Digital Solutions, a wholly owned subsidiary of Religare Broking, was created to house the e-governance business, and the transfer of that undertaking from RBL was approved by the NCLT in June 2025. - MIC Insurance Web Aggregator, an IRDAI-registered web aggregator acquired in December 2023, had its operations suspended and its license surrender approved in May 2026 due to financial stress.

Documents — Religare Enterprises Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/o9kl7pzkl13q7nw17m3nljml.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/letylzag8y3ovmf65wtij6co.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/uhrk9afbftyzb4b386qy2sn2.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/ipov6s9aykiq91na987ribpu.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/5oq9a11k19fsx3cs8hehwo8d.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/3qrroldkvpl9y0yjf6yvrkr8.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/qzo70e3vnlxo695cb5ay4oz5.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/llefwhdq8kee626v3bqobiji.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/cxmcg7kqmf9mnss77mrov6ig.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/chh8suxjbhsgc28evz5qghbl.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/rz203olcuth0l6x1cl1h92k5.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/wsijp8xp7ydvthvffra2xz3u.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/c9jr7ds21v5fe23uwnqcjj4w.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/f9wv4inz2fez0wzmvx72w2nv.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/ituv56cxqrdwqtn2302k75kp.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/cmdexyc85txoqxkg93lzkiih.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/yqzmdryn00d0o82d4zzk66pp.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/recn4qevsh5ul5ntn4fresj0.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/mvf446m6ae031uyq2yctm4sa.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/6lypype36he8ncd9ondml3zi.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/o8toxmedc0uhfxoipch56x3m.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/omgaf1bwgcvriuy0dt8jjol2.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/avhe9isjg7kd7kh7rl025z7z.pdf

Concall Transcript Summaries — Religare Enterprises Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3ARELIGARE/transcript-notes/202606/o9kl7pzkl13q7nw17m3nljml.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3ARELIGARE/transcript-notes/202603/letylzag8y3ovmf65wtij6co.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3ARELIGARE/transcript-notes/202512/uhrk9afbftyzb4b386qy2sn2.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3ARELIGARE/transcript-notes/202509/ipov6s9aykiq91na987ribpu.pdf